Transcranial Magnetic Stimulation for Cannabis Use

(iCURE Trial)

This trial explores whether repetitive transcranial magnetic stimulation (rTMS) can help reduce cannabis use. Researchers aim to determine if this treatment decreases attention to cannabis-related cues, which often lead to relapse. Participants will receive either the real rTMS treatment or a sham (placebo) version and will be monitored for changes in cannabis use and brain activity. The trial seeks frequent cannabis users who are seeking treatment and can commit to attending multiple sessions over a two-week period. As an unphased trial, it offers participants the opportunity to contribute to groundbreaking research in addiction treatment.

Research has shown that intermittent Theta Burst Stimulation (iTBS), a type of brain stimulation, is well-tolerated. One study found that using iTBS for two weeks did not cause harmful effects, indicating its safety for short-term use. Researchers have also tested it safely in various conditions, such as alcohol use disorder. While further research is beneficial, these findings suggest that iTBS could be a safe option for reducing cannabis cravings.¹²³⁴⁵

Transcranial Magnetic Stimulation (TMS) for cannabis use is unique because it offers a non-invasive, brain-targeted approach to managing addiction. Unlike standard treatments for cannabis use disorder, which often involve behavioral therapies and medications, TMS uses iTBS (intermittent Theta Burst Stimulation) to directly modulate brain activity. Researchers are excited about TMS because it targets specific neural circuits associated with craving and addiction, potentially reducing cannabis use without the side effects associated with traditional medications. This method could represent a groundbreaking shift in treating cannabis dependence, offering rapid results with minimal discomfort.

Research has shown that intermittent theta burst stimulation (iTBS), a form of brain stimulation, might help reduce substance use. Studies have found that iTBS can lower the number of drinking days for people who use alcohol and reduce cravings for cocaine and methamphetamine. This treatment targets brain areas linked to addiction, potentially decreasing the focus on drug-related cues that can cause relapse. In this trial, participants will receive either active iTBS or a sham treatment to evaluate its effects on cannabis use disorder. While iTBS has proven effective for other substance use issues, its effects on cannabis use disorder remain under investigation. Early results suggest it might reduce cannabis cravings and use by altering how the brain responds to cannabis-related cues.¹²³⁵⁶